1. Home
  2. AFYA vs TRVI Comparison

AFYA vs TRVI Comparison

Compare AFYA & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Afya Limited

AFYA

Afya Limited

HOLD

Current Price

$14.05

Market Cap

1.3B

Sector

Real Estate

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$14.63

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AFYA
TRVI
Founded
1999
2011
Country
Brazil
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
AFYA
TRVI
Price
$14.05
$14.63
Analyst Decision
Hold
Strong Buy
Analyst Count
5
11
Target Price
$17.00
$21.55
AVG Volume (30 Days)
66.0K
1.7M
Earning Date
05-08-2026
05-05-2026
Dividend Yield
4.90%
N/A
EPS Growth
N/A
31.91
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$10.43
N/A
Revenue Next Year
$7.15
N/A
P/E Ratio
$9.30
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.00
$5.38
52 Week High
$19.76
$16.12

Technical Indicators

Market Signals
Indicator
AFYA
TRVI
Relative Strength Index (RSI) 41.03 58.93
Support Level $13.06 $10.07
Resistance Level $15.50 $16.12
Average True Range (ATR) 0.55 0.79
MACD -0.10 -0.09
Stochastic Oscillator 7.36 56.64

Price Performance

Historical Comparison
AFYA
TRVI

About AFYA Afya Limited

Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: